EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials

Evgenia Gourgari iD, Gitanjali Srivastava iD, Aaron S Kelly iD, Donna Mojdami, Dachuang Cao iD, Madhumita A Murphy, Chrisanthi A Karanikas iD, Clare J Lee iD

Obesity · 2025

DOI: 10.1002/oby.24348 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, 2025. Written by Evgenia Gourgari and 7 co-authors. Institution: Division of Pediatric Endocrinology, Department of Pediatrics, Georgetown University, Washington, DC, USA. Major MEDLINE topics: Obesity. Cited 3 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Eli Lilly and Company.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

People with early‐onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity‐related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with tirzepatide in people with early‐ versus later‐onset obesity.

Methods

Participants ( N = 3782) from SURMOUNT‐1, SURMOUNT‐3, and SURMOUNT‐4 randomized to tirzepatide or placebo were included. Baseline characteristics and changes in BW and cardiometabolic risk factors at 72/88 weeks were assessed.

Results

In SURMOUNT‐1, participants with early‐ versus later‐onset obesity had longer mean obesity duration (20 ± 12 vs. 11 ± 8 years), higher BMI (40 ± 7 vs. 37 ± 6 kg/m 2 ) and waist circumference (WC, 118 ± 16 vs. 112 ± 14 cm), and lower HbA1c (5.48% ± 0.4% vs. 5.60% ± 0.4%), triglycerides (median 120 vs. 130 mg/dL), and systolic blood pressure (SBP; 121 ± 13 vs. 125 ± 13 mmHg) at baseline (all p ≤ 0.004). At 72 weeks, improvements with tirzepatide in BW (−23% vs. −22%), WC (−22 vs. −19 cm), HbA1c (−0.51% vs. −0.52%), triglycerides (−32% vs. −31%), and SBP (−8 vs. −8 mmHg) were similar between subgroups. Similar improvements were observed in SURMOUNT‐3 and SURMOUNT‐4.

Conclusions

In this post hoc analysis, participants with early‐ versus later‐onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups. Trial Registration ClinicalTrials.gov identifiers: NCT04184622, NCT04657016, NCT04660643 image

Subjects

MeSH terms (MEDLINE)

ObesityHumansMaleFemaleTriglyceridesAdultWaist CircumferenceBody Mass IndexBlood PressureYoung AdultAge of OnsetAdolescentBody WeightGlycated HemoglobinCardiometabolic Risk FactorsTreatment OutcomeTirzepatide

Author keywords

early‐onsetobesitytirzepatide

Substances

TriglyceridesGlycated HemoglobinTirzepatide

Authors and institutions

  • Division of Pediatric Endocrinology, Department of Pediatrics, Georgetown University, Washington, DC, USA.
  • Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Vanderbilt Weight Loss Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

ORCID profiles: Evgenia Gourgari, Gitanjali Srivastava, Aaron S Kelly, Dachuang Cao, Chrisanthi A Karanikas, Clare J Lee

Funding

  • Eli Lilly and Company

Cite

APA

Gourgari, E., Srivastava, G., Kelly, A. S., Mojdami, D., Cao, D., Murphy, M. A., Karanikas, C. A., & Lee, C. J. (2025). Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials. Obesity. https://doi.org/10.1002/oby.24348

Vancouver

Gourgari E, Srivastava G, Kelly AS, Mojdami D, Cao D, Murphy MA, et al. Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials. Obesity. 2025. doi:10.1002/oby.24348

BibTeX
@article{Gourgari2025,
  author = {Gourgari, Evgenia and Srivastava, Gitanjali and Kelly, Aaron S and Mojdami, Donna and Cao, Dachuang and Murphy, Madhumita A and Karanikas, Chrisanthi A and Lee, Clare J},
  title = {Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials},
  journal = {Obesity},
  year = {2025},
  doi = {10.1002/oby.24348}
}
Start for free →